Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic Steatohepatitis Is Associated With Liver‐Related Outcomes and All‐Cause Mortality in Chronic Hepatitis B
Hannah Choi, Willem Pieter Brouwer, Wayel M.R. Zanjir, et al.
Hepatology (2019) Vol. 71, Iss. 2, pp. 539-548
Closed Access | Times Cited: 166

Showing 1-25 of 166 citing articles:

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
Mohammed Eslam, Philip N. Newsome, Shiv Kumar Sarin, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 1, pp. 202-209
Open Access | Times Cited: 3173
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
Mohammed Eslam, Arun J. Sanyal, Jacob George, et al.
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1999-2014.e1
Open Access | Times Cited: 2561
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Mohammed Eslam, Shiv Kumar Sarin, Vincent Wai‐Sun Wong, et al.
Hepatology International (2020) Vol. 14, Iss. 6, pp. 889-919
Open Access | Times Cited: 629
Hepatitis B
Wen‐Juei Jeng, George Papatheodoridis, Anna S. Lok
The Lancet (2023) Vol. 401, Iss. 10381, pp. 1039-1052
Closed Access | Times Cited: 271
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 254
Global burden of hepatitis B virus: current status, missed opportunities and a call for action
Yao‐Chun Hsu, Daniel Q. Huang, Mindie H. Nguyen
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 8, pp. 524-537
Closed Access | Times Cited: 248
TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis
Jinchao Hou, Jue Zhang, Ping Cui, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 4
Open Access | Times Cited: 156
Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China
Yebei Liang, Hongli Chen, Yuexing Liu, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 1, pp. 88-97
Open Access | Times Cited: 135
Asian perspective on NAFLD-associated HCC
Terry Cheuk‐Fung Yip, Hye Won Lee, Wah‐Kheong Chan, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 3, pp. 726-734
Closed Access | Times Cited: 106
Geographical similarity and differences in the burden and genetic predisposition of NAFLD
Terry Cheuk‐Fung Yip, Eduardo Vilar‐Gómez, Salvatore Petta, et al.
Hepatology (2022) Vol. 77, Iss. 4, pp. 1404-1427
Closed Access | Times Cited: 71
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 51
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
Shang‐Chin Huang, Chun‐Jen Liu
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 320-331
Open Access | Times Cited: 42
Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa
Gamal Shiha, Khalid Alswat, Maryam Al Khatry, et al.
˜The œLancet. Gastroenterology & hepatology (2020) Vol. 6, Iss. 1, pp. 57-64
Closed Access | Times Cited: 135
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease
Yuemin Nan, Jihong An, Jianfeng Bao, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 2, pp. 454-461
Open Access | Times Cited: 98
MAFLD: Renovation of clinical practice and disease awareness of fatty liver
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, et al.
Hepatology Research (2021) Vol. 52, Iss. 5, pp. 422-432
Closed Access | Times Cited: 89
Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy
Yameng Sun, Xiaoning Wu, Jialing Zhou, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 18, Iss. 11, pp. 2582-2591.e6
Open Access | Times Cited: 88
MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
Yingxin Xian, Jianping Weng, Fen Xu
Chinese Medical Journal (2020) Vol. 134, Iss. 1, pp. 8-19
Open Access | Times Cited: 84
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B
Laurens A. van Kleef, Hannah Choi, Willem Pieter Brouwer, et al.
JHEP Reports (2021) Vol. 3, Iss. 5, pp. 100350-100350
Open Access | Times Cited: 82
Systematic review with meta‐analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B
Qi Zheng, Biyao Zou, Yuankai Wu, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 9, pp. 1100-1109
Closed Access | Times Cited: 58
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 790-801
Open Access | Times Cited: 55
Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysis
Xianhua Mao, Ka Shing Cheung, Cheng-Zhi Peng, et al.
Hepatology (2022) Vol. 77, Iss. 5, pp. 1735-1745
Closed Access | Times Cited: 49
HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure
Maryam Moini, Scott Fung
Viruses (2022) Vol. 14, Iss. 4, pp. 657-657
Open Access | Times Cited: 44
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
Yu Jun Wong, Vy H. Nguyen, Hwai‐I Yang, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 3, pp. 705-720
Open Access | Times Cited: 31
Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B
Shang‐Chin Huang, Tung‐Hung Su, Tai‐Chung Tseng, et al.
Hepatology International (2023) Vol. 17, Iss. 5, pp. 1139-1149
Closed Access | Times Cited: 30
NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
Piero Portincasa
Internal and Emergency Medicine (2023) Vol. 18, Iss. 4, pp. 993-1006
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top